Sign in
4

Changes in Ownership

Spyre Therapeutics, Inc. Filed Acc 0001209191-20-064066

Options or other derivatives

  • Director acquired 47,200 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Lawton Alison Frances Director 2020-12-15 Grant or award · Director Stock Option (right to buy) +47,200 47,200 D: show line 1 in the form
Loading xslF345X03/doc4.xml…